Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

Print E-mail
Monday, 27 October 2014 15:59

HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental eXpanded (PLX)-RAD cells.

Read more...
 

Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program

Print E-mail
Monday, 27 October 2014 15:23

 

New York, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, and Albert Einstein College of Medicine of Yeshiva University, a research-intensive medical school in Bronx, NY, started development of an antibody construct labeled with actinium 225 using a novel technology that potentially allows for the expansion of use of the Company’s proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates.
Read more...
 

TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease

Print E-mail
Wednesday, 22 October 2014 22:39
SEATTLE, WASHINGTON--TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM  vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
Read more...
 

PROVECTUS’ INTRALESIONAL PV-10 CLINICAL DATA TO BE PRESENTED TO THE 2014 INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH

Print E-mail
Thursday, 16 October 2014 18:07
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.
Read more...
 

RELMADA THERAPEUTICS REINFORCES BALANCE SHEET WITH $15.2 MILLION FROM EXERCISE OF WARRANTS

Print E-mail
Thursday, 16 October 2014 18:04

New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014.

Read more...
 

INC RESEARCH SIGNS AGREEMENT TO PERFORM FDA DUE DILIGENCE AUDIT OF REGULATORY DOCUMENTS FOR PROVECTUS BIOPHARMACEUTICALS

Print E-mail
Tuesday, 14 October 2014 13:57

KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

Read more...
 

Pluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims

Print E-mail
Tuesday, 07 October 2014 10:23
Read more...
 

Healthcare Valuation Experts Tackle Advanced Concepts

Print E-mail
Monday, 06 October 2014 16:06
Healthcare valuation and consulting experts seeking help in navigating the treacherous regulatory landscape of healthcare can’t afford to miss an in-depth symposium this December presented by the National Association of Certified Valuators and Analysts™ (NACVA®) and the Consultants’ Training Institute™ (CTI™).  The Advanced Healthcare Valuation and Consulting Symposium will be held December 12–13, 2014, in San Diego, CA at the Solamar Hotel.
Read more...
 

CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial

Print E-mail
Friday, 03 October 2014 13:27

Vienna, VA-- CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).

Read more...
 

Clinical Decision Support Tools Can Help Doctors Quickly and Accurately Diagnose Ebola and other Infectious Diseases

Print E-mail
Friday, 03 October 2014 09:03

ROCHESTER, NY--Four years ago, the Institute of Medicine recommended the Department of Health and Human Services promote the use of clinical decision support tools to ensure doctors quickly and accurately detect and diagnose bioterrorism and infectious disease outbreaks.

Read more...
 
<< Start < Prev 1 > >>

Page 1 of 2

Newsletter

BioMedReports Immunomedics Provides Update On Phase 2 Study Of Isactuzumab Govitecan; Hemispherx Reports New Evidence of Amp... http://t.co/z7wEE2pkui
11hreplyretweetfavorite
BioMedReports Movers: Johnson & Johnson, Perrigo Company, AstraZeneca, Acadia Healthcare Company, Charles River Laboratories... http://t.co/sF6jvpM24E
15hreplyretweetfavorite
BioMedReports Cara Therapeutics Announces Positive Results Of Peripheral Opioid; POZEN Appoints Senior VP and Chief Business... http://t.co/yoqxKE9IsH
Benzinga.com supporter Seeking Alpha Certified